Drug survival of biologic agents in patients with psoriatic arthritis from a medical center in southern Taiwan
Sebastian Yu1, Yu-Hsiang Tsao2, Hung-Pin Tu3, Cheng-Che E Lan4
1 Department of Dermatology, Kaohsiung Medical University Hospital; Department of Dermatology, College of Medicine; Neuroscience Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan 2 Department of Medical Research, Division of Medical Statistics and Bioinformatics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan 3 Department of Public Health and Environmental Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan 4 Department of Dermatology, Kaohsiung Medical University Hospital; Department of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
Correspondence Address:
Dr. Cheng-Che E Lan Department of Dermatology, College of Medicine, Kaohsiung Medical University, 100 Shih-Chuan 1st Rd, Kaohsiung 807378 Taiwan Dr. Hung-Pin Tu Department of Public Health and Environmental Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, 100 Shih-Chuan 1st Rd, Kaohsiung 807378 Taiwan
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/ds.ds_8_22
|
Background: Psoriasis is a chronic inflammatory disease involving the skin and/or joints. Till 2016, there were five biologic agents for psoriatic arthritis treatment in Taiwan: etanercept, adalimumab, golimumab, ustekinumab, and secukinumab. Although European guidelines recommend tumor necrosis factor-α (TNF-α) inhibitors as the first-line biologic agents for axial disease of psoriatic arthritis, the drug survival of biologic agents in Asian populations remains unclear. Objectives: We investigated 5-year drug survival of biologic agents in patients with psoriatic arthritis. Methods: We used Kaohsiung Medical University Hospital Research Database to evaluate real-world 5-year drug survival of biologic agents for psoriatic arthritis in a medical center from southern Taiwan. Results: The 5-year drug survival rates of ustekinumab, etanercept, and adalimumab were significantly different. Ustekinumab and etanercept showed higher 5-year survival rates for psoriatic disease than adalimumab. Golimumab and secukinumab had a short follow-up time to obtain a conclusive 5-year survival rate. Conclusion: Considering that TNF-α inhibitors are often the first-line biologic agents for psoriatic arthritis in guidelines in western countries, the finding that ustekinumab is superior to TNF-α inhibitor adalimumab in terms of 5-year survival for psoriatic disease may imply that the therapeutic response of biologic agents may differ between different ethnic groups.
|